ONLINE GOLD AND SILVER TREND DAILY ALERTS: 23RD NOVEMBER 2010

By Editorial Team -

XAU/USD (Gold): Bought (Long) at USD 1364.55/ounce (23 Nov 2010) Close position if price goes below USD 1337.00/oz  (support at 50 DMA (daily moving average))
XAG/USD (Silver): Bought (Long) at USD 26.55/ounce (19 Nov 2010) Maintain long position. Close position if price goes below USD 25.95/oz (support at 20 DMA (daily moving average))






Comments

Post a Comment

Pages

Popular posts from this blog

Top 10 ETFs for AI and Tech Growth in September 2025: Best Picks for Diversification (Ranked)

By -
Image
As of late August 2025, the AI and tech growth sector remains robust, fueled by ongoing innovations in generative AI, semiconductors, automation, and quantum computing. Drawing from recent financial analyses, here are the top 10 ETFs recommended for exposure to AI and tech growth, with an emphasis on diversification across subsectors like software, hardware, robotics, and emerging tech. These selections are based on expert recommendations, performance momentum (using 1-year returns where available), expense ratios, and AUM. Remember, market performance fluctuates, and diversification doesn't ensure gains—assess your risk profile and consult a professional advisor. Update: Top 10 ETF Picks for AI and Tech Growth in October 2025 : Best Funds to Buy Now for Growth, Safety, and Diversification (Ranked) As of August 31, 2025, we've re-ranked the ETFs for AI and tech growth based on their 1-year trailing returns and AUM, in descending order.  1. ARK Autonomous Technology & Roboti...
Read more

Top 10 Pharmaceutical Companies by Revenue and Market Cap in 2025 (September Edition)

By -
Image
Here are the top 10 pharmaceutical companies as of 2025, updated based on second quarter 2025 revenue data. AstraZeneca, Novartis and Vertex each posted 12% sales increases, offering more evidence of their upward trajectories in recent years. Credit:  fiercepharma.com Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). Updates: Drug Stock Rally Helps Push Dow and S&P 500 to Records — WSJ ( Oct 2, 2025 ) Eli Lilly's (LLY) shares jumped 8.6% amid reports of a drug-pricing deal between the White House and the pharmaceutical industr...
Read more

Top 10 Stocks and ETFs Poised to Outperform in October 2025

By -
Image
In light of the recent stock market tumble on October 10, 2025, triggered by renewed threats of massive tariffs on Chinese imports announced by President Trump, investors are facing heightened uncertainty. This event has exacerbated ongoing volatility that began earlier in the year with the broader 2025 stock market crash, which started on April 2 amid new tariff policies.  With the Federal Reserve maintaining its rate-cutting trajectory into October 2025 amid heightened market volatility and sector rotation, opportunities are emerging in small caps, semiconductors/AI, value stocks, and gold miners as hedges. Based on recent analyses from Zacks, Morningstar, Yahoo Finance, and ETF experts, we've compiled a forward-looking list of 20 recommendations (10 stocks and 10 ETFs) expected to capitalize on these trends through the end of October and into Q4. Selections emphasize high-conviction picks with upward earnings revisions, undervaluation, and momentum ...
Read more

Top 10 ETF Picks for October 2025: Best Funds to Buy Now for Growth, Safety, and Diversification Amid Recent Market Volatility

By -
Image
In light of the recent stock market tumble on October 10, 2025, triggered by renewed threats of massive tariffs on Chinese imports announced by President Trump, investors are facing heightened uncertainty. This event has exacerbated ongoing volatility that began earlier in the year with the broader 2025 stock market crash, which started on April 2 amid new tariff policies.  Major U.S. indices sank, with technology stocks hit hardest, amplifying concerns about a potential deeper crash. Jamie Dimon, CEO of JPMorgan Chase, has warned of a significantly higher risk of a U.S. stock market crash than many anticipate, estimating a 30% chance within the next two years. Despite this, opportunities remain in resilient sectors. Gold and bitcoin have surged to record highs as hedges against inflation, rising U.S. debt, and a weakening dollar, making safe-haven and diversified ETFs particularly attractive.  This updated list of top 10 ETFs blends global equ...
Read more

Best Gold and Silver ETFs of 2025: Should You Buy Today? (October 2025 Edition)

By -
Image
As we enter Q4 2025, gold prices have rallied way above $4,000 per ounce, with analysts forecasting potential climbs above $4,100 by year-end amid ongoing geopolitical tensions, central bank buying, and economic uncertainty. Silver, often called "gold's little brother," has rallied above $50 per ounce, driven by industrial demand in solar and electronics, with projections for prices to reach $$55 per ounce by the end of October and potentially higher into November. Gold and silver ETFs have shown strong performance in 2025, surpassing the S&P 500 amid inflation concerns, geopolitical tensions, and central bank buying.  This article updates the best-performing gold and silver ETFs based on recent data, including 1-year returns, assets under management (AUM), expense ratios, and key notes, evaluating their pros, cons, and attractiveness in the current market.The best gold and silver ETFs of 2025 are noted for exceptional performance, low expense ratios, and reliable tra...
Read more

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights

By -
Image
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. Update:  Top Bitcoin, Ethereum, and XRP ETFs to Watch in October 2025 : Updated Performance, AUM, and Investment Insights 1. Leading XRP ETFs in 2025 ProSha...
Read more

Top 10 Stock Picks for October 2025: Best Funds to Buy Now for Growth, Safety, and Diversification Amid Recent Market Volatility

By -
Image
In light of the recent stock market tumble on October 10, 2025, triggered by renewed threats of massive tariffs on Chinese imports announced by President Trump, investors are facing heightened uncertainty. This event has exacerbated ongoing volatility that began earlier in the year with the broader 2025 stock market crash, which started on April 2 amid new tariff policies.  With the Federal Reserve maintaining its rate-cutting trajectory into October 2025 amid heightened market volatility and sector rotation, opportunities are emerging in small caps, semiconductors/AI, value stocks, and gold miners as hedges. Based on recent analyses from Zacks, Morningstar, Yahoo Finance, and ETF experts, we've compiled a forward-looking list of 10 recommendations expected to capitalize on these trends through the end of October and into Q4. Selections emphasize high-conviction picks with upward earnings revisions, undervaluation, and momentum in resilient sectors. Below, we've incorporated re...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more

Top 10 ETF Picks for AI and Tech Growth in October 2025: Best Picks for Diversification (Ranked)

By -
Image
Here are the top 10 ETF picks for AI and tech growth in October 2025, along with insights on whether they are worth considering for investment at this time. The ranking prioritizes growth (high 1-year and YTD returns), safety (lower beta and volatility for reduced risk), and diversification (higher number of holdings and broader sector exposure beyond pure tech/semiconductors). These ETFs were selected from popular recommendations in recent analyses. Pure AI-focused funds like ARKQ and CHAT score high on growth but lower on diversification due to concentrated holdings. Broader tech ETFs like VGT and QQQ offer better balance for safety and diversification. This guide focuses on AI's boom in semiconductors, robotics, and quantum computing, recommending a mix of high-growth (e.g., ARKQ) and diversified (e.g., VGT) picks for balanced portfolios amid market volatility.Valuations use premium/discount to NAV (>0.5% overvalued, <-0.5% undervalued) from recent data; small premiums ind...
Read more

Top 10 Food Companies by Revenue (2025)

By -
Image
Based on the most recent 2025 revenue data, here are the top 10 food companies ranked by revenue: Top 10 Food Companies by Revenue (2025) 1. Nestlé (Switzerland) Revenue:  $101.54 billion Key Brands: Nescafe, KitKat, Maggi, Purina, Waters Notes:  World's largest food company, with a diverse portfolio including bottled water, coffee, frozen foods, and nutrition products. Nestlé Health Science (NHSc), a subsidiary of Nestlé, owns a variety of supplement brands. Some of the most notable ones include: Garden of Life, Vital Proteins, Pure Encapsulations, Wobenzym, Douglas Laboratories, Persona Nutrition, Genestra, Orthica, Minami, AOV, Klean Athlete, Nature's Bounty, Solgar, Osteo Bi-Flex, and Sundown. 2. Ahold Delhaize  (Netherlands) Revenue:  $96.22 billion Notes: Major global food retailer and distributor. 3. PepsiCo (USA) Revenue: $91.52 billion Key Brands: Pepsi, Lay's, Gatorade, Tropi...
Read more